Asthma Disease Market Report 2025

The asthma disease market size has grown strongly in recent years. It will grow from $24.63 billion in 2024 to $25.93 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth during the historic period can be attributed to the increasing prevalence of asthma in urban areas, higher air pollution levels in industrialized regions, growing awareness of asthma symptoms and diagnosis, increased use of corticosteroids and bronchodilators, and improved healthcare access in developing countries.

The asthma disease market size is expected to see strong growth in the next few years. It will grow to $31.56 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The projected growth in the forecast period can be attributed to the rising adoption of biologics for severe asthma, increasing demand for personalized medicine, growing investments in asthma research, wider use of digital health and remote monitoring technologies, and expansion of telemedicine services for asthma care. Key trends expected include advancements in biologic therapies for severe asthma, development of smart inhaler technologies, creation of AI-powered asthma monitoring tools, innovations in personalized treatment strategies, and the growth of digital health platforms for remote asthma management.

The increasing prevalence of respiratory disorders is expected to drive the growth of the asthma disease market moving forward. Respiratory disorders include a range of diseases that affect the lungs and breathing, such as chronic obstructive pulmonary disease (COPD), bronchitis, and asthma. The rise in respiratory disorders is largely due to exposure to particulate matter and nitrogen oxides, which irritate and inflame the airways, causing breathing difficulties and exacerbating conditions like asthma. These respiratory diseases can lead to inflammation and airway remodeling, which trigger or worsen asthma symptoms. For example, in December 2023, the National Library of Medicine, a US-based national library, reported that by 2050, COPD cases in low- and middle-income countries are expected to more than double those in high-income countries, with sub-Saharan Africa projected to see a 59% increase and become the global leader in COPD prevalence and cases by 2040. Consequently, the growing prevalence of respiratory disorders is boosting the asthma disease market.

Key companies in the asthma disease market are focusing on developing treatments such as monoclonal antibody therapies to improve treatment effectiveness and patient outcomes. Monoclonal antibody therapy is a targeted treatment that uses lab-created proteins to mimic the immune system’s ability to combat harmful agents, providing more precise and effective management of chronic diseases like asthma. For instance, in June 2022, the National Institutes of Health (NIH), a US-based medical research agency, initiated the PANDA trial (Preventing Asthma in High-Risk Kids) to assess the monoclonal antibody dupilumab as a treatment for asthma in urban youth. The PANDA trial is a Phase 2, randomized, placebo-controlled study involving around 240 children aged 6 to 17 with poorly controlled type 2 inflammation and high allergic asthma living in low-income urban areas. Participants receive subcutaneous injections every two weeks for one year in addition to standard asthma care, with a 2:1 randomization to dupilumab or placebo. The trial also includes mechanistic studies using nasal swabs and blood samples to analyze gene expression, especially during respiratory viral infections, aiming to understand the molecular pathways behind asthma exacerbations and treatment responses in this high-risk pediatric group.

In January 2024, GSK plc, a UK-based pharmaceutical company, acquired Aiolos Bio Inc. for an undisclosed amount. This acquisition allows GSK to strengthen its respiratory treatment portfolio and support long-term growth by combining Aiolos Bio’s innovative therapies with GSK’s global presence to better serve patients worldwide. Aiolos Bio Inc. is a US-based clinical-stage biopharmaceutical company specializing in asthma treatments.

Major players in the asthma disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, and Generate Biomedicines.

North America was the largest region in the asthma disease market in 2024. The regions covered in asthma disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the asthma disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asthma disease market consists of revenues earned by entities by providing services such as diagnosis, screening, allergy testing, immunotherapy, education, counselling, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The asthma disease market also includes sales of peak flow meters, spirometers, allergy medications, biologic drugs, air purifiers, humidifiers, smart inhalers, wearable asthma monitors, and allergen-proof bedding. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The asthma disease market research report is one of a series of new reports that provides asthma disease market statistics, including asthma disease industry global market size, regional shares, competitors with a asthma disease market share, asthma disease market segments, market trends and opportunities, and any further data you may need to thrive in the asthma disease industry. This asthma disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Asthma is a chronic inflammatory condition of the airways, marked by repeated episodes of wheezing, shortness of breath, chest tightness, and coughing - often occurring at night or early morning. It involves airflow obstruction that is typically reversible, either on its own or with treatment, and is linked to heightened airway sensitivity to triggers like allergens, exercise, or cold air.

The main treatment options for asthma include controller medications, rescue medications, biologics, and combination therapies. Controller medications are long-term drugs taken daily to prevent symptoms and asthma attacks. Asthma can be caused by various factors such as allergic asthma, non-allergic asthma, exercise-induced asthma, and occupational asthma. The severity levels range from mild intermittent to severe persistent. Administration routes include oral, inhaled, intravenous, and others. These treatments are utilized across multiple settings including hospitals, home care, specialty clinics, and more.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.